Statement of Principles concerning restless legs syndrome (Reasonable Hypothesis) (No. 113 of 2022)

This instrument, the Repatriation Medical Authority Statement of Principles concerning restless legs syndrome (Reasonable Hypothesis) (No. 113 of 2022), sets out the medical definitions and the factual factors that the Repatriation Medical Authority (RMA) treats as sufficient to raise a reasonable hypothesis that restless legs syndrome (RLS) or death from RLS is connected with a person’s relevant service. It is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (see section 3) and commences on 21 November 2022 (section 2). The instrument expressly repeals the prior Statement of Principles concerning restless legs syndrome No. 20 of 2014 (section 4).

Mechanically, the instrument does three things. First, it defines what the RMA means by “restless legs syndrome” for the purposes of veterans’ and MRCA claims (section 7(2) to (4)). That definition integrates clinical features, frequency and duration thresholds, functional impact, and an exclusion for conditions that solely account for the presentation. Second, it lists discrete pre‑existing disorders, exposures and clinical findings which, if present and related to the person’s relevant service, constitute the minimum that must exist to raise a reasonable hypothesis connecting RLS (or death from RLS) to service (section 9). The listed factors are separated into those relevant to clinical onset and those relevant to clinical worsening, and include precise timing and quantitative thresholds in several instances. Third, it supplies definitional detail in the Schedule 1 dictionary that fixes laboratory cutoffs, measurement conventions and medication lists that operationalise the factors (Schedule 1).

The instrument applies to claims within the statutory regimes specified in section 5: claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies. It does not itself create offences, monetary entitlements or administrative procedures; instead it operates as the RMA’s medical statement used by decision makers in applying the VEA and MRCA to individual claims (see section 3 and section 8, which records the RMA’s view about medical‑scientific evidence).

The practical effect is that proof of RLS being related to service will typically require evidence that one or more of the factors in section 9 existed at the relevant time and was related to the person’s relevant service as required by section 10. The Schedule contains measurement thresholds that convert many clinical concepts into documentary or laboratory evidence requirements, for example serum ferritin <30 micrograms per litre for iron deficiency, BMI ≥30 for obesity, and glomerular filtration rate thresholds for chronic renal failure. The instrument also ties the RLS ICD code G25.81 to the RMA definition while clarifying that the RMA’s textual definition in section 7(2) controls for this instrument (section 7(3) and (4)).

Users should treat the document as an evidentiary standard tied to statutory claims processes: it prescribes the minimum combinations of diagnosis, comorbidity, exposure and timing the RMA regards as raising a reasonable hypothesis. It also cross‑references other Statements of Principles for injuries or diseases mentioned in section 9 (section 11), meaning evidence of overlapping conditions may trigger application of a different SOP as part of the assessment.

The instrument is built around a few interlocking legal and clinical concepts.

Restless legs syndrome definition. The RMA defines RLS as a sensorimotor neurological disorder with four core clinical features: an urge to move the legs typically accompanied by unpleasant sensations, onset or worsening during rest or inactivity, partial or total relief by movement, and circadian worsening in the evening or night (section 7(2)(a)(i)-(iv)). In addition, the RMA requires frequency and persistence thresholds , at least three times per week for at least three consecutive months , and significant distress or impairment in functioning (section 7(2)(b)(i)-(ii)). There is an explicit exclusion where those features are “solely accounted for by another medical or behavioural condition” (section 7(2)(b)(iii)).

Reasonable hypothesis standard. The instrument specifies the factors that must exist before “a reasonable hypothesis has been raised connecting restless legs syndrome or death from restless legs syndrome with the circumstances of a person’s relevant service” (section 9 introductory text). It is therefore not a statement of causation on the balance of probabilities. Rather, it sets out the minimum factual scenarios that will support raising a reasonable hypothesis for the purposes of the VEA and MRCA claims processes.

Onset versus worsening. The instrument distinguishes between factors that apply at the time of clinical onset (items 1 to 18 of section 9) and factors that apply to clinical worsening (items 19 to 38 of section 9). Subsection 10(2) further qualifies that the factors in subsections 9(19) to 9(38) apply only to material contribution or aggravation where the person’s RLS was suffered or contracted before or during (but did not arise out of) the person’s relevant service.

Objective thresholds and temporal windows. The Schedule translates many clinical concepts into specific objective thresholds and time windows. Examples include iron deficiency defined as serum ferritin <30 micrograms per litre, being obese defined as BMI ≥30 (Schedule 1), chronic renal failure defined by GFR <15 mL/min/1.73 m2 for at least three months or need for renal replacement therapy or chronic dialysis, smoking exposure measured in pack‑years with the cessation window of five years, and a 30‑day window for exposure to specified drugs before onset or worsening (section 9(6) and corresponding Schedule definitions). For augmentation, the requirement is continuous use of a dopaminergic agent or tramadol for at least three months before the clinical worsening (section 9(37) and Schedule).

Interplay with other Statements of Principles. Section 11 provides that where a factor in section 9 refers to an injury or disease that is the subject of another SOP under subsection 196B(2) of the VEA, the factors in that other SOP apply according to its terms. This makes the instrument modular and capable of cross‑application where multiple SOPs overlap.

This Statement of Principles affects several identifiable groups in the veteran and claims ecosystem.

Veterans and former members of the Australian Defence Force. The immediate class affected is persons making claims under the VEA or MRCA for RLS or death from RLS where their claim is within the scope of section 120A of the VEA or section 338 of the MRCA (section 5). The instrument applies to veterans, members of Peacekeeping Forces, and members of the Forces as defined by the VEA and MRCA through the defined term “relevant service” in Schedule 1. Relevant service includes operational, peacekeeping, hazardous and British nuclear test defence service under the VEA and warlike and non‑warlike service under the MRCA (Schedule 1 definitions).

Decision makers in the Department of Veterans’ Affairs. The document is used by DVA decision makers and medical assessors to determine whether the factual threshold of a reasonable hypothesis is met in claims processing. The instrument sets out the RMA’s determinative medical criteria and threshold factors; decision makers will rely on these when applying the statutory tests in the VEA and MRCA.

Treating clinicians and medical examiners. Doctors, specialists and allied health professionals preparing reports for claims will be affected by the instrument’s lab and documentation thresholds. The Schedule sets specific measurement cutoffs for ferritin, BMI, GFR and lipid levels, and prescribes how medication exposures are to be measured. Clinicians will need to structure clinical notes and investigations to speak to those thresholds where RLS claims are in issue.

Applicants’ representatives. Lawyers, veterans’ advocates, claims agents and medical advocates who prepare case files and submissions will need to align evidentiary material to the instrument. For instance, they must gather medication histories demonstrating ongoing prescription and timing, laboratory reports showing ferritin or lipid levels, BMI calculations, dialysis records, surgery or anaesthesia records, smoking histories quantified in pack‑years, and any diagnostic records for neurological disorders, Parkinson’s disease, multiple sclerosis, sleep apnoea or narcolepsy.

Family members and executors in death claims. The instrument treats death from RLS as death from a terminal event contributed to by RLS (section 7(5)), so dependants and executors pursuing entitlements or pensions based on a contributorily related death will need to assemble both terminal event documentation (for example, cause of death certificates listing pneumonia or cardiac arrest) and evidence tying RLS as a contributing condition.

This instrument does not create administrative duties in the general sense of imposing new obligations on private parties. Its legal effect is procedural and evidentiary within the VEA and MRCA claim regimes. The key operative duties and rights flow from how the instrument is used by decision makers and how claimants can rely on it.

Duty on decision makers to apply the Statement as an evidentiary standard. The RMA made this Statement under subsection 196B(2) of the VEA (section 3). Decision makers assessing claims under section 120A of the VEA or section 338 of the MRCA (section 5) must treat these factors as the minimal factual circumstances that, if present and related to relevant service, raise a reasonable hypothesis. That creates an administrative duty to consult and weigh the instrument when determining reasonable hypothesis questions in the relevant claims processes.

Right of claimants to rely on the listed factors. Claimants who can addu ce evidence that one or more of the factors in section 9 existed at the relevant time and was related to their relevant service have the legal right to assert that a reasonable hypothesis has been raised. The instrument sets a catalogue of sufficient factors; a claimant meeting any one of them satisfies the RMA’s minimum threshold under this Statement for raising a reasonable hypothesis. For example, evidence of iron deficiency (ferritin <30 micrograms per litre) at the time of onset satisfies factor 2 (section 9(2) and Schedule 1 definition).

Duty to show the relationship to relevant service. Section 10(1) requires that the existence of any factor in section 9 must be related to the relevant service rendered by the person. The Statement does not shift the statutory onus, but it makes clear that mere presence of a listed factor is not enough; the factor must be connected to the person’s relevant service. Thus claimants have a procedural right to have their evidence considered for relation to service, and decision makers have the duty to assess that relationship.

Temporal duty when relying on worsening factors. Subsection 10(2) imposes a limiting duty: subsections 9(19) to 9(38), which concern worsening, apply only to material contribution to or aggravation of RLS where the claimant suffered or contracted RLS before or during (but not arising out of) relevant service. This has the practical duty for claimants to demonstrate baseline RLS pre‑service or during service to invoke the worsening pathway.

Duty to use other SOPs where relevant. Section 11 requires that if a factor in section 9 refers to an injury or disease that is the subject of another SOP under subsection 196B(2) of the VEA, then the factors in that SOP apply according to its terms. Decision makers must therefore ensure that cross‑referenced SOPs are engaged and applied properly when the factor refers to such a condition.

The Statement of Principles itself does not prescribe penalties, fines or criminal sanctions. It is an administrative instrument under subsection 196B(2) of the VEA (section 3) that supplies a medical evidentiary framework used in the statutory claims processes under the VEA and MRCA. Consequently, enforcement is not by penal sanction but by administrative decision making under the veterans’ entitlements framework.

Administrative enforcement and outcomes. The instrument is used by decision makers to determine whether the factual threshold of a reasonable hypothesis is met in a claim. Administrative outcomes that can flow from a decision informed by this instrument include acceptance or rejection of a claim, entitlement to pensions or treatment benefits under the VEA/MRCA, or recognition of service connection for RLS or death from RLS. While these are not described in the instrument itself, the instrument’s role is to guide whether those administrative outcomes should be engaged by showing a reasonable hypothesis.

No independent statutory enforcement mechanism. The document does not create an independent enforcement body or authorise penalties for non‑compliance. There is no written power in this instrument to impose coercive obligations on private entities. Its practical force derives from its use by DVA and MRCA decision makers in claims adjudication.

Evidentiary consequences for non‑production of supporting material. Because the instrument translates many clinical concepts into defined thresholds (for example ferritin <30 micrograms per litre for iron deficiency; BMI ≥30 for obesity; GFR <15 mL/min/1.73 m2 for chronic renal failure), failure to produce supporting laboratory or clinical documentation will materially affect a claimant’s ability to satisfy the factors in section 9. The consequence is practical: claims may fail for lack of evidence to raise the reasonable hypothesis. That consequence is administrative rather than punitive.

Interaction with other claimant review and appeals regimes. Although the instrument does not itself set appeal or review mechanisms, administrative decisions under the VEA and MRCA that rely on this instrument will remain subject to the statutory review and appeal processes provided by those Acts and associated administrative law frameworks. The instrument can therefore indirectly influence the scope of reviewable decisions, but it does not change the review pathways.

No criminal liability or civil sanction expressed. There are no provisions within this instrument that create criminal offences or civil penalties for providing false information or for other conduct. The usual statutory provisions in the VEA, MRCA or general law dealing with false or misleading statements remain outside the instrument and are not altered by it.

This Statement of Principles functions within the statutory architecture of the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. It is made under subsection 196B(2) of the VEA (section 3) and applies to claims to which section 120A VEA or section 338 MRCA apply (section 5). The instrument is therefore an administrative medical standard used to support decision making under those primary Acts.

Subordination to the enabling Acts. The instrument relies on and is subordinate to the VEA framework. It does not create entitlements nor does it alter substantive statutory tests in those Acts; instead it expresses the RMA’s view of medical‑scientific evidence that establishes a reasonable hypothesis for service connection. Decision makers applying the VEA or MRCA will use it as the medical statement that assists in answering statutory questions such as whether a disease is service related for benefit eligibility. The instrument cannot, of itself, change the statutory tests or create entitlements outside those Acts.

Cross‑application with other Statements of Principles. Section 11 creates a direct interaction with other Statements of Principles made under subsection 196B(2) of the VEA. Where a factor in section 9 refers to an injury or disease covered by another SOP, then the factors in that other SOP apply “in accordance with the terms of that Statement of Principles as in force from time to time.” That means decision makers must consult and apply other SOPs where, for example, peripheral neuropathy, spinal cord lesions, Parkinson’s disease or multiple sclerosis are implicated. This mechanism integrates the instrument into the broader network of RMA SOPs rather than treating it as standalone.

Reference to ICD‑10‑AM codes. Subsection 7(3) notes that while RLS attracts ICD‑10‑AM code G25.81, the meaning in the instrument is that given in subsection 7(2). Subsection 7(4) specifies the edition (Tenth Edition, effective date 1 July 2017) and thus anchors the RMA’s medical taxonomy to recognised classification standards. This interaction affects how administrative medical coding is reconciled with the RMA’s textual definition.

Interaction with clinical records and evidence law. The Schedule sets objective clinical thresholds such as ferritin <30 micrograms per litre, BMI calculations, GFR thresholds, lipid level cutoffs, and pack‑year calculations. Those thresholds require the admission and assessment of medical records, pathology reports and medication histories under the evidentiary rules that apply to administrative decision making. The instrument therefore interacts functionally with evidence rules in administrative law and with the record‑keeping obligations of medical practitioners and institutions.

This instrument carries a limited amendment history contained within the instrument itself. The principal change recorded is the repeal of the earlier Statement of Principles concerning restless legs syndrome No. 20 of 2014 (Federal Register of Legislation No. F2014L00307), effected by section 4 of the present instrument. The current instrument is identified as No. 113 of 2022 and is dated 21 October 2022 (cover material). It commences on 21 November 2022 (section 2).

Replacement of prior SOP. Section 4 expressly repeals the 2014 SOP, meaning the 2014 document no longer operates for claims falling within the temporal and substantive scope of the new instrument. The text does not list other amendments to this instrument since its making. Users need to treat No. 113 of 2022 as the operative RMA Statement for RLS from its commencement date.

Effect on cross‑referenced SOPs. Section 11 contemplates that other Statements of Principles made under subsection 196B(2) of the VEA will apply where a factor in section 9 refers to an injury or disease that is the subject of another SOP. That introduces a dynamic amendment interaction: while this instrument has a discrete history, the factors drawn in from other SOPs may change over time as those SOPs are amended. The instrument anticipates this by specifying that the other SOPs apply “as in force from time to time,” so the effective factors list for any given claimant may be a composite of the present document and contemporaneously amended SOPs elsewhere.

Reference to ICD‑10‑AM edition. The instrument ties one element of its meaning to the ICD‑10‑AM Tenth Edition with an effective date of 1 July 2017 (section 7(4)). If ICD coding systems are later updated and a decision maker relies on a subsequent edition, the instrument itself remains tied to the edition specified unless otherwise amended. Any amendment to change the ICD edition to which the instrument refers would, therefore, be a discrete amendment.

No recorded statutory amendments inside the instrument. The instrument does not record subsequent changes or variations to its own text beyond the repeal of the 2014 SOP. There is no internal schedule of amendments or transitional rules included in the text provided. Practitioners should therefore check the Federal Register of Legislation or the RMA website for any subsequent variations, revocations or replacement SOPs made after the commencement date.

Transitional considerations implicit. The repeal in section 4 implies that claims decided after 21 November 2022 should be assessed against the new Statement. The instrument does not state transitional arrangements for claims lodged prior to the commencement date, or for decisions already made under the 2014 SOP; those transitional arrangements, if any, will be governed by primary legislation or administrative policy rather than this instrument.

This Statement of Principles does not contain, and does not purport to record, any judicial decisions. The instrument itself does not cite litigation, and there are no cases or proceedings referred to within its text. The RMA records in section 8 that it is “of the view that there is sound medical‑scientific evidence” indicating that RLS and death from RLS can be related to relevant service, but no judicial or administrative reviews are documented in the instrument.

Implications for litigation. Because the instrument provides an administrative evidentiary standard used in claims adjudication, litigation relating to its application would occur in the statutory administrative review and judicial review pathways available under the VEA and MRCA frameworks, and in the courts where claimants seek merits or judicial review of decisions. However, the instrument does not itself list, summarise or cite any litigation authority one way or the other.

No internal footnotes on precedent. The document is purely a statement of medical factors and definitions; it does not discuss how tribunals, courts or review bodies have treated prior SOPs or RLS disputes. There is no internal litigation history to analyse within this text.

Consequences for evidence in litigation. In disputes that proceed to review, the instrument will operate as the RMA’s medical statement. Parties in litigation are likely to address whether the administrative decision maker correctly applied the instrument and whether the evidentiary threshold of a reasonable hypothesis was properly assessed in light of the instrument’s factors and Schedule definitions. The instrument’s precise thresholds and timing windows (for example ferritin <30 micrograms per litre, BMI ≥30, 30‑day windows for medication exposure, three month continuous dopaminergic use for augmentation) will therefore be focal points in contested claims. While the instrument contains no litigation record, it does create predictable issues that would commonly be litigated, such as the sufficiency of medical evidence to meet the Schedule cutoffs and the proper interpretation of subsections 10(1) and 10(2) relating to relationship to service.

Absence of case law in the instrument. As the instrument does not name cases, and the developer instructions require that only cases named in provided sources be mentioned, no cases are referenced here. Practitioners seeking litigation history will need to consult tribunal and court records outside this text to locate any decisions that have considered SOP No. 113 of 2022 or the preceding 2014 SOP.

Practical note. Because the instrument is a determinative administrative statement, any material litigation history relevant to its interpretation or application will exist outside the instrument and should be sought from administrative law databases, tribunal records, and court judgments if required.

The instrument contains several technical features and traps for the unwary that materially affect claim strategy, evidence gathering, and adjudication.

Objective cutoffs replace clinical vagueness. Several items that might in clinical practice be assessed on a sliding scale are instead given precise numerical thresholds in the Schedule. Iron deficiency is ferritin <30 micrograms per litre; dyslipidaemia is defined through specific HDL, LDL, triglyceride, or total cholesterol thresholds or regular lipid‑normalising therapy; chronic renal failure is GFR <15 mL/min/1.73 m2 for at least three months or need for renal replacement therapy; obesity is BMI ≥30; and pack‑year calculations are specified with explicit equivalencies (Schedule 1). If a claimant’s laboratory figures sit above or below these cutoffs by a small margin, the claimant may fail to meet the listed factor even though a clinician might see the state as clinically relevant.

Timing windows are narrow and consequential. Several factors require exposure within tight temporal windows. For example, taking a drug from the specified list must be on ongoing prescription and within the 30 days before clinical onset or worsening (sections 9(6) and 9(24)). Spinal anaesthesia must have occurred within 30 days before onset or worsening (sections 9(9) and 9(27)). Smoking requires at least 5 pack‑years and, if ceased, onset or worsening must be within five years of cessation (sections 9(10) and 9(28)). Failure to document precise dates for medication, anaesthesia, or smoking cessation can be decisive.

Different tests for onset versus worsening. The instrument separates onset factors (9(1)-(18)) from worsening factors (9(19)-(38)), with subsection 10(2) adding the qualification that the worsening factors apply only where RLS was suffered or contracted before or during (but did not arise out of) relevant service. That creates a potential evidentiary gap for claimants whose RLS first arose out of service: they cannot later rely on the worsening factors in 9(19)-(38) unless the condition pre‑existed in the required temporal posture.

Cross‑reference to other SOPs can change the applicable factors. Section 11 requires that if a factor in section 9 refers to a disease with its own SOP, then the factors in that SOP apply. Practically that means a factor such as “peripheral neuropathy” will not be assessed solely under this instrument but under the relevant peripheral neuropathy SOP. Claimants and advisers must locate and satisfy the other SOPs’ requirements as well. This can raise unexpected evidentiary thresholds if the other SOP has stricter or different definitions.

Complying with this Statement of Principles means assembling documentary and clinical evidence that maps precisely to the definitions, timing windows and thresholds in the instrument so that a reasonable hypothesis of service connection can be raised. The following practical tasks align evidence collection with the instrument’s requirements.

Confirm diagnosis against section 7(2). Ensure the clinical diagnosis of RLS in a claimant’s records tracks the RMA definition: urge to move the legs with accompanying sensations, rest‑provoked symptoms, relief by movement, nocturnal predominance, frequency at least three times per week for at least three consecutive months, and evidence of significant distress or functional impairment (section 7(2)). Medical opinions should explicitly address each criterion in section 7(2)(a) and (b) and explain why no other medical or behavioural condition solely accounts for the presentation.

Gather laboratory and objective data matching Schedule thresholds. For factors that rely on numerical cutoffs, obtain and include the relevant test results:

• Serum ferritin values to show iron deficiency as ferritin <30 micrograms per litre for factors 9(2) and 9(20).
• Renal function reports showing GFR values and dates or dialysis/transplant records to demonstrate chronic renal failure per the Schedule for factors 9(3) and 9(21).
• Lipid panel results meeting the dyslipidaemia thresholds or evidence of ongoing lipid‑normalising therapy per the Schedule for factors 9(15) and 9(33).
• BMI calculations (weight and height) over time to demonstrate BMI ≥30 for a continuous five year period where relying on factors 9(11) or 9(29).
• Smoking histories quantified in pack‑years, with dates of cessation where applicable, to support factors 9(10) and 9(28).
• Pathology or specialist reports confirming diagnoses such as Parkinson’s disease, multiple sclerosis, narcolepsy or obstructive sleep apnoea where relevant.

Document medication histories precisely. For factors that require medication exposure:

• Obtain pharmacy dispensing records, prescription charts, or medical notes showing ongoing prescription and dates of use for drugs in the specified list within 30 days before onset or worsening (sections 9(6), 9(24) and Schedule).
• For augmentation claims (section 9(37)), produce records showing continuous use of a dopaminergic agent (including levodopa and pramipexole) or tramadol for at least three months before the clinical worsening, with dosage and continuity evidence.